The goal of the renewal application continues to be the understanding of the pathogenesis of non-cardiac pulmonary edema that occurs after insults elsewhere in the body (e.g. sepsis or non-thoracic trauma and shock). Two major hypothesis will be studied. The first is that indirect lung microvascular injury is mediated by formed elements of the blood, i.e. is blood-borne. The second is that many elements of what is commonly called the """"""""acute inflammatory response"""""""" combine to cause changes characteristic of acute lung injury. The performance of repeated limited bronchoalveolar lavage in patients who are at high risk for the adult respiratory distress syndrome (ARDS), in those who have the acute syndrome, and in those who are resolving the syndrome is central to the investigation of these hypotheses. Lavage fluid will be fractionated and components examined for the presence of mediators of cellular activation, for surfactant activity, and for acute phase proteins. Results of these studies will be correlated with clinical variables collected simultaneously. Mechanisms of lung injury in animals and in isolated perfused lungs will be investigated concurrently. Potential mediators of endotoxin-induced lung injury including the cytokines interleukin l and tumor necrosis factor, leukotrienes, and platelet activating factor will be assayed for. In vitro studies using purified mediators and cultured cells will look at cell to cell interactions in up-regulating and down-regulating cellular injury and the acute inflammatory response. Animal models and in vitro systems have been specifically chosen to study aspects that cannot be well-defined in humans, e.g., ultrastructural morphology and biology of limited injury, mechanisms of resolution and structural reorganization, and inter-organ interactions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL030572-07
Application #
3106679
Study Section
Special Emphasis Panel (SRC (01))
Project Start
1983-09-30
Project End
1993-11-30
Budget Start
1989-12-01
Budget End
1990-11-30
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Saint Louis University
Department
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Ahmed, N; Thorley, R; Xia, D et al. (1996) Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am J Respir Crit Care Med 153:1141-7
Stephenson, A H; Sprague, R S; Weintraub, N L et al. (1996) Inhibition of cytochrome P-450 attenuates hypoxemia of acute lung injury in dogs. Am J Physiol 270:H1355-62
Heuertz, R M; Ahmed, N; Webster, R O (1996) Peptides derived from C-reactive protein inhibit neutrophil alveolitis. J Immunol 156:3412-7
Kew, R R; Mollison, K W; Webster, R O (1995) Binding of Gc globulin (vitamin D binding protein) to C5a or C5a des Arg is not necessary for co-chemotactic activity. J Leukoc Biol 58:55-8
Sabharwal, A K; Bajaj, S P; Ameri, A et al. (1995) Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 151:758-67
Kew, R R; Fisher, J A; Webster, R O (1995) Co-chemotactic effect of Gc-globulin (vitamin D binding protein) for C5a. Transient conversion into an active co-chemotaxin by neutrophils. J Immunol 155:5369-74
Weintraub, N L; Stephenson, A H; Sprague, R S et al. (1995) Relationship of arachidonic acid release to porcine coronary artery relaxation. Hypertension 26:684-90
Weintraub, N L; Joshi, S N; Branch, C A et al. (1994) Relaxation of porcine coronary artery to bradykinin. Role of arachidonic acid. Hypertension 23:976-81
Heuertz, R M; Xia, D; Samols, D et al. (1994) Inhibition of C5a des Arg-induced neutrophil alveolitis in transgenic mice expressing C-reactive protein. Am J Physiol 266:L649-54
Lonigro, A J; Weintraub, N L; Branch, C A et al. (1994) Endothelium-dependent relaxation to arachidonic acid in porcine coronary artery: is there a fourth pathway? Pol J Pharmacol 46:567-77

Showing the most recent 10 out of 88 publications